OPTIMIZATION OF LOCAL THERAPY FOR VAGINAL INFECTIONS AND DYSBIOSES

The authors investigated the clinical and immunological efficacy of the interferon inducer 5% cycloferon liniment (Scientific Technological Pharmaceutical Firm «Polysan», Saint Petersburg) during intravaginal monotherapy for nonspecific vaginitis (NV), Candida vaginitis (CV), and bacterial vaginosis (BV), as well as its immunomodulatory effect.
During a prospective study, the total clinical and microbiological efficiencies of a course of therapy were 74%; in the clinical groups, it was 68.2% for NV, 93.7% for BV, and 75% for CV. A placebo-controlled study showed that the clinical efficacy of the agent was 88.8%; there was a 2.6-fold reduction in the total incidence of the pathological types of vaginal biocenosis as compared to placebo.
The drug is well tolerated by the patients; it causes no allergic reactions or other adverse events.
The basic mechanism of the drug's immunomodulatory effect is to affect local vaginal immunity and it is
manifested by the following immunological changes in vaginal secretions: an increase in vaginal tissue-blood
barrier permeability; compensation for baseline diminished local IgG and IgA synthesis not only due to the higher
diffusion of immunoglobulins from the bloodstream, but also due to the normalization and increase of their local
synthesis.
The use of the agent as a basic drug is promising and warranted during a course of immune-oriented therapy for infectious and inflammatory diseases and dysbioses of the lower female genital tract.
The main use regimen for 5% cycloferon liniment to correct vaginal microbiocenosis is as follows: daily intravaginal instillations of 5 ml for 10 days.

cycloferon, vaginal infections and dysbioses, local immunity, immunomodulation